Therapeutic drug monitoring of imatinib in patients with chronic myeloid leukaemia: Experience from Oran HUE
1 Pharmacovigilance department, University Hospital Establishment of Oran, Algeria.
2 Mohamed Lamine Debaghine University Hospital Center, Algiers, Algeria.
3 Tlemcen Faculty of Medicine, Abu Bakr Belkaid University, Tlemcen, Algeria.
4 Hematology department, University Hospital Establishment of Oran, Algeria.
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 25(03), 201–209.
Article DOI: 10.30574/gscbps.2023.25.3.0533
Publication history:
Received on 15 November 2023; revised on 25 December 2023; accepted on 27 December 2023
Abstract:
Imatinib, a first-line treatment for chronic myelogenous leukemia, presents significant interindividual pharmacokinetic variability. The correlation between the plasma exposure of Imatinib and its pharmacological effects makes this drug a good candidate for pharmacological therapeutic monitoring in addition to the usual monitoring tests. We introduced monitoring of Imatinib in 27 patients suffering from chronic myelogenous leukemia. According to the dosage results, dosage adaptation recommendations were proposed to clinicians in patients outside the targeted therapeutic range. The goal was to achieve an optimal response to Imatinib, prevent its adverse effects and improve adherence to treatment.
Keywords:
Imatinib; Therapeutic drug monitoring; Chronic myelogenous leukemia; Dosage adaptation; Major molecular response
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
